CG Oncology Statistics
Total Valuation
CG Oncology has a market cap or net worth of $5.44 billion. The enterprise value is $4.71 billion.
Important Dates
The last earnings date was Friday, February 27, 2026, before market open.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CG Oncology has 84.44 million shares outstanding. The number of shares has increased by 23.69% in one year.
| Current Share Class | 84.44M |
| Shares Outstanding | 84.44M |
| Shares Change (YoY) | +23.69% |
| Shares Change (QoQ) | +4.35% |
| Owned by Insiders (%) | 0.97% |
| Owned by Institutions (%) | 93.57% |
| Float | 69.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,346.99 |
| Forward PS | 1,030.53 |
| PB Ratio | 6.91 |
| P/TBV Ratio | 7.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,165.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.63, with a Debt / Equity ratio of 0.01.
| Current Ratio | 24.63 |
| Quick Ratio | 24.09 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -21.67% and return on invested capital (ROIC) is -15.97%.
| Return on Equity (ROE) | -21.67% |
| Return on Assets (ROA) | -15.42% |
| Return on Invested Capital (ROIC) | -15.97% |
| Return on Capital Employed (ROCE) | -25.08% |
| Weighted Average Cost of Capital (WACC) | 10.78% |
| Revenue Per Employee | $28,451 |
| Profits Per Employee | -$1.13M |
| Employee Count | 142 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +132.92% in the last 52 weeks. The beta is 1.19, so CG Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | +132.92% |
| 50-Day Moving Average | 55.72 |
| 200-Day Moving Average | 39.51 |
| Relative Strength Index (RSI) | 60.45 |
| Average Volume (20 Days) | 1,373,806 |
Short Selling Information
The latest short interest is 9.29 million, so 11.01% of the outstanding shares have been sold short.
| Short Interest | 9.29M |
| Short Previous Month | 9.50M |
| Short % of Shares Out | 11.01% |
| Short % of Float | 13.46% |
| Short Ratio (days to cover) | 11.51 |
Income Statement
In the last 12 months, CG Oncology had revenue of $4.04 million and -$161.00 million in losses. Loss per share was -$2.08.
| Revenue | 4.04M |
| Gross Profit | -117.25M |
| Operating Income | -190.77M |
| Pretax Income | -161.00M |
| Net Income | -161.00M |
| EBITDA | -189.33M |
| EBIT | -190.77M |
| Loss Per Share | -$2.08 |
Full Income StatementBalance Sheet
The company has $742.16 million in cash and $7.02 million in debt, with a net cash position of $735.13 million or $8.71 per share.
| Cash & Cash Equivalents | 742.16M |
| Total Debt | 7.02M |
| Net Cash | 735.13M |
| Net Cash Per Share | $8.71 |
| Equity (Book Value) | 752.60M |
| Book Value Per Share | 9.33 |
| Working Capital | 728.64M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$132.35 million and capital expenditures -$134,000, giving a free cash flow of -$132.48 million.
| Operating Cash Flow | -132.35M |
| Capital Expenditures | -134,000 |
| Free Cash Flow | -132.48M |
| FCF Per Share | -$1.57 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -4,722.13% |
| Pretax Margin | -3,985.02% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CG Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.69% |
| Shareholder Yield | -23.69% |
| Earnings Yield | -2.96% |
| FCF Yield | -2.43% |
Analyst Forecast
The average price target for CG Oncology is $71.27, which is 10.58% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $71.27 |
| Price Target Difference | 10.58% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 224.87% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CG Oncology has an Altman Z-Score of 36.09 and a Piotroski F-Score of 3.
| Altman Z-Score | 36.09 |
| Piotroski F-Score | 3 |
